2018 ASH meeting to feature new CAR-T therapies for myeloma
Bispecific antibodies like Amgen's AMG 420 could present some competition to CAR-Ts. But could sequential use of the therapies - which target the same antigen - be possible?
Janssen sees a potential myeloma CAR-T edge, exec says at BIO
The company plans to open its upcoming trial of a Chinese-developed CAR-T at four initial sites later this year.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.